(Q40100316)

17 September 2017

Clinical judgment versus biomarker prostate cancer gene 3: which is best when determining the need for repeat prostate biopsy? (English)

1 reference

17 September 2017

0 references

0 references

4

1 reference

17 September 2017

Bertrand Tombal

1

1 reference

17 September 2017

Gerald L Andriole

2

1 reference

17 September 2017

Alexandre de la Taille

3

1 reference

17 September 2017

Alexander Haese

5

1 reference

17 September 2017

Mesut Remzi

6

1 reference

17 September 2017

Mark Speakman

7

1 reference

17 September 2017

Louis Smets

8

1 reference

17 September 2017

Herman Stoevelaar

9

1 reference

17 September 2017

language of work or name

English

0 references

publication date

21 March 2013

1 reference

17 September 2017

1 reference

17 September 2017

81

1 reference

17 September 2017

998-1004

1 reference

17 September 2017

5

1 reference

Screening for prostate cancer

17 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.11.069

EAU guidelines on prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.11.069

Detection of prostate cancer via biopsy in the Medicare-SEER population during the PSA era.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.11.069

Prostate cancer testing following a negative prostate biopsy: over testing the elderly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.11.069

Repeat prostate biopsy and the incremental risk of clinically insignificant prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.11.069

A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.11.069

Biopsy and treatment decisions in the initial management of prostate cancer and the role of PCA3; a systematic analysis of expert opinion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.11.069

Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.11.069

Current status of transrectal ultrasound-guided prostate biopsy in the diagnosis of prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.11.069

DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.11.069

PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.11.069

Prostate cancer antigen 3 score accurately predicts tumour volume and might help in selecting prostate cancer patients for active surveillance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.11.069

Critical assessment of preoperative urinary prostate cancer antigen 3 on the accuracy of prostate cancer staging.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.11.069

Effect of dutasteride on the risk of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.11.069

Development and validation of a nomogram for predicting a positive repeat prostate biopsy in patients with a previous negative biopsy session in the era of extended prostate sampling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.11.069

10.1016/J.UROLOGY.2012.11.069

7 January 2021

Identifiers

DOI

1 reference

17 September 2017

1 reference